Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals.

Adolescent Adult Aged Aged, 80 and over BNT162 Vaccine COVID-19 / epidemiology COVID-19 Vaccines / administration & dosage Child Child, Preschool Female Humans Infant Infant, Newborn Male Middle Aged RNA, Messenger / genetics SARS-CoV-2 / pathogenicity

Journal

Nature medicine

ISSN: 1546-170X

Titre abrégé: Nat Med

Pays: United States

ID NLM: 9502015

Informations de publication

Date de publication:
08 2021

Historique:

received: 30 04 2021

accepted: 26 05 2021

pubmed: 16 6 2021

medline: 28 8 2021

entrez: 15 6 2021

Statut: ppublish

Résumé

The BNT162b2 mRNA vaccine is highly effective against SARS-CoV-2. However, apprehension exists that variants of concern (VOCs) may evade vaccine protection, due to evidence of reduced neutralization of the VOCs B.1.1.7 and B.1.351 by vaccine sera in laboratory assays. We performed a matched cohort study to examine the distribution of VOCs in infections of BNT162b2 mRNA vaccinees from Clalit Health Services (Israel) using viral genomic sequencing, and hypothesized that if vaccine effectiveness against a VOC is reduced, its proportion among breakthrough cases would be higher than in unvaccinated controls. Analyzing 813 viral genome sequences from nasopharyngeal swabs, we showed that vaccinees who tested positive at least 7 days after the second dose were disproportionally infected with B.1.351, compared with controls. Those who tested positive between 2 weeks after the first dose and 6 days after the second dose were disproportionally infected by B.1.1.7. These findings suggest reduced vaccine effectiveness against both VOCs within particular time windows. Our results emphasize the importance of rigorously tracking viral variants, and of increasing vaccination to prevent the spread of VOCs.

Identifiants

DOI: 10.1038/s41591-021-01413-7 PMID: 34127854 PMC: PMC8363499

pubmed: 34127854

doi: 10.1038/s41591-021-01413-7

pii: 10.1038/s41591-021-01413-7

pmc: PMC8363499

doi:

Substances chimiques

COVID-19 Vaccines 0

RNA, Messenger 0

BNT162 Vaccine N38TVC63NU

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

1379-1384

Subventions

Organisme : EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council)

ID : 852223

Informations de copyright

Références

Dagan, N. et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med. 384, 1412–1423 (2021).

doi: 10.1056/NEJMoa2101765

Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).

doi: 10.1056/NEJMoa2034577

Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 372, eabg3055 (2021).

doi: 10.1126/science.abg3055

Davies, N. G. et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature 593, 270–274 (2021).

doi: 10.1038/s41586-021-03426-1

Tegally, H. et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. Preprint at medRxiv https://doi.org/10.1101/2020.12.21.20248640 (2020).

Naveca, F. et al. Phylogenetic relationship of SARS-CoV-2 sequences from Amazonas with emerging Brazilian variants harboring mutations E484K and N501Y in the Spike protein. Virological.org https://virological.org/t/phylogenetic-relationship-of-sars-cov-2- sequences-from-amazonas-with-emerging- brazilian-variants-harboring-mutations- e484k-and-n501y-in-the-spike-protein/585 (2021).

Liu, Y. et al. Neutralizing activity of BNT162b2-elicited serum. N. Engl. J. Med. 384, 1466–1468 (2021).

doi: 10.1056/NEJMc2102017

Xie, X. et al. Neutralization of SARS-CoV-2 spike 69/70 deletion E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat. Med. 27, 620–621 (2021).

doi: 10.1038/s41591-021-01270-4

Collier, D. A. et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature 593, 136–141 (2021).

doi: 10.1038/s41586-021-03412-7

Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell 184, 2348–2361.e6 (2021).

doi: 10.1016/j.cell.2021.02.037

Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130–135 (2021).

doi: 10.1038/s41586-021-03398-2

Kuzmina, A. et al. SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera. Cell Host Microbe 29, 522–528 (2021).

doi: 10.1016/j.chom.2021.03.008

Korber, B. et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 182, 812–827 (2020).

doi: 10.1016/j.cell.2020.06.043

Liu, Y. et al. Neutralizing activity of BNT162b2-elicited serum—preliminary report. N. Engl. J. Med. 384, 1466–1468 (2021).

doi: 10.1056/NEJMc2102017

Tarke, A. et al. Negligible impact of SARS-CoV-2 variants on CD4

South African variant found in about 1% of all positive tests. MOH https://www.gov.il/en/departments/news/22022021-01 (2021).

Planas, D. et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat. Med. 27, 917–924 (2021).

doi: 10.1038/s41591-021-01318-5

Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. https://doi.org/10.1038/s41591-021-01377-8 (2021).

Marks, M. et al. Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. Lancet Infect. Dis. 21, 629–636 (2021).

doi: 10.1016/S1473-3099(20)30985-3

Walsh, E. E. et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N. Engl. J. Med. 383, 2439–2450 (2020).

doi: 10.1056/NEJMoa2027906

Optimising the COVID-19 vaccination programme for maximum short-term impact. GOV.UK https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact (2021).

Abu-Raddad, L. J. et al. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N. Engl. J. Med. https://doi.org/10.1056/NEJMc2104974 (2021).

Greaney, A. J. et al. Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies. Preprint at bioRxiv https://doi.org/10.1101/2020.12.31.425021 (2021).

Weisblum, Y. et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife 9, e61312 (2020).

doi: 10.7554/eLife.61312

Greaney, A. J. et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe 29, 44–57 (2021).

doi: 10.1016/j.chom.2020.11.007

Starr, T. N. et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science 371, 850–854 (2021).

doi: 10.1126/science.abf9302

Garcia-Beltran, W. F. et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 184, 2372–2383.e9 (2021).

doi: 10.1016/j.cell.2021.03.013

Walker, A. S. et al. Increased infections, but not viral burden, with a new SARS-CoV-2 variant. Preprint at medRxiv https://doi.org/10.1101/2021.01.13.21249721 (2021).

Levine-Tiefenbrun, M. et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat. Med. 27, 790–792 (2021).

doi: 10.1038/s41591-021-01316-7

Petter, E. et al. Initial real world evidence for lower viral load of individuals who have been vaccinated by BNT162b2. Preprint at medRxiv https://doi.org/10.1101/2021.02.08.21251329 (2021).

COVID-19 Dashboard (Israeli Ministry of Health); https://datadashboard.health.gov.il/COVID-19/general (accessed 26 May 2021)

Itokawa, K. et al. Disentangling primer interactions improves SARS-CoV-2 genome sequencing by multiplex tiling PCR. PLoS ONE 15, e0239403 (2020).

doi: 10.1371/journal.pone.0239403

Zhang, X. et al. pTrimmer: an efficient tool to trim primers of multiplex deep sequencing data. BMC Bioinformatics 20, 236 (2019).

doi: 10.1186/s12859-019-2854-x

Gelbart, M. et al. Drivers of within-host genetic diversity in acute infections of viruses. PLoS Pathog. 16, e1009029 (2020).

doi: 10.1371/journal.ppat.1009029

Altschul, S. F. et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25, 3389–3402 (1997).

doi: 10.1093/nar/25.17.3389

Rambaut, A. et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat. Microbiol. 5, 1403–1407 (2020).

doi: 10.1038/s41564-020-0770-5

Dudas, G. et al. Travel-driven emergence and spread of SARS-CoV-2 lineage B.1.620 with multiple VOC-like mutations and deletions in Europe. Preprint at medRxiv https://doi.org/10.1101/2021.05.04.21256637 (2021).

McKinney, W. Data structures for statistical computing in Python. In Proc. 9th Python in Science Conference (2010).

Hunter, J. D. Matplotlib: a 2D graphics environment. Comput. Sci. Eng. 9, 90–95 (2007).

doi: 10.1109/MCSE.2007.55

Villanueva, R. A. M. & Chen, Z. J. ggplot2: Elegant Graphics for Data Analysis (Taylor & Francis, 2019).

Katoh, K. et al. MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. Nucleic Acids Res. 30, 3059–3066 (2002).

doi: 10.1093/nar/gkf436

Guindon, S. et al. in Bioinformatics for DNA Sequence Analysis (ed Posada, D.) 113–137 (Springer, 2009).